The research company Curasight reports, as planned, no revenue during the fourth quarter. The focus is on developing the company into a clinical drug development company. The operating result was DKK -16.2 million (-11.9). The result after tax was DKK -15.3 million (-11). Earnings per share amounted to DKK -0.32 (-0.58)."Q4 2025 was characterized by strong momentum as we further developed the company into a clinical drug development company, paving the way for uTREAT – our first-in-class RLT platform that targets uPAR across multiple tumor types. uTREAT is supported by uTRACE, our clinically validated uPAR PET diagnostic platform built on the same ligand. uTRACE enables a true theranostic approach by supporting patient selection, confirming tumor target engagement, and de-risking development through validation with human imaging," says CEO Ulrich Krasilnikoff in the report. Curasight dosed the first patient in its Phase 1 study of uTREAT in glioblastoma, moving the program into active clinical development. The company reiterates that it is on track to report topline data in 2026. "uTRACE continued to make progress in the Phase 2 study in prostate cancer and is also on track for topline data in 2026. With a strengthened balance sheet after DKK 63.4 million in cash and DKK 40 million in new and renegotiated loan facilities, we enter 2026 focused on disciplined execution and the delivery of key clinical milestones," Krasilnikoff continues. Curasight, MDKKQ4-2025Q4-2024Net sales00Operating result-16.2-11.9Net result-15.3-11Earnings per share, DKK-0.32-0.58